{"id":"fludrocortisone-acetate-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Fluid retention / edema"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a mineralocorticoid receptor agonist, fludrocortisone acetate acts on the collecting duct of the kidney to promote sodium retention and water reabsorption while increasing urinary potassium loss. This leads to expansion of intravascular volume and elevation of blood pressure. It is used primarily in conditions characterized by aldosterone deficiency or severe hypotension.","oneSentence":"Fludrocortisone acetate is a synthetic mineralocorticoid that enhances sodium reabsorption and potassium excretion in the distal renal tubules, thereby increasing blood volume and blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:12:55.129Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute hypotension / shock"},{"name":"Adrenocortical insufficiency"},{"name":"Salt-wasting syndromes"}]},"trialDetails":[{"nctId":"NCT06136650","phase":"PHASE3","title":"A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-18","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms","enrollment":1314},{"nctId":"NCT06353386","phase":"PHASE1, PHASE2","title":"Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-05-20","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":220},{"nctId":"NCT06136624","phase":"PHASE3","title":"Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-31","conditions":"Prostate Cancer Metastatic","enrollment":1310},{"nctId":"NCT06136598","phase":"PHASE1","title":"A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-01-30","conditions":"Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer","enrollment":14},{"nctId":"NCT06979596","phase":"PHASE2","title":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-08-11","conditions":"Malignant Neoplasm","enrollment":250},{"nctId":"NCT06104449","phase":"PHASE1","title":"A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-11-14","conditions":"Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer","enrollment":6},{"nctId":"NCT07451886","phase":"PHASE2","title":"Adjunctive Fludrocortisone in Septic Shock","status":"NOT_YET_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2026-04-01","conditions":"Sepsis, Septic Shock, Sepsis - to Reduce Mortality in the Intensive Care Unit","enrollment":32},{"nctId":"NCT07383103","phase":"PHASE4","title":"Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock","status":"RECRUITING","sponsor":"Northern Jiangsu People's Hospital","startDate":"2026-03-02","conditions":"Septic Shock","enrollment":336},{"nctId":"NCT06860243","phase":"PHASE1","title":"A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-13","conditions":"Hepatic Impairment, Healthy Participants","enrollment":16},{"nctId":"NCT06801236","phase":"PHASE1","title":"Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Acerand Therapeutics (Hong Kong) Limited","startDate":"2025-05-12","conditions":"Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)","enrollment":67},{"nctId":"NCT06409364","phase":"PHASE2","title":"FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage","status":"RECRUITING","sponsor":"The George Institute","startDate":"2025-08-13","conditions":"Aneurysmal Subarachnoid Hemorrhage","enrollment":524},{"nctId":"NCT06814132","phase":"PHASE1","title":"A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-07","conditions":"Kidney Failure, Chronic, End-Stage Kidney Disease, Renal Failure, Chronic","enrollment":24},{"nctId":"NCT04280497","phase":"NA","title":"Rapid Recognition of Corticosteroid Resistant or Sensitive Sepsis","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-04-10","conditions":"Sepsis","enrollment":1800},{"nctId":"NCT07007910","phase":"PHASE1","title":"Phase I Study of HSK46575 in Patients With Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","startDate":"2024-12-18","conditions":"m CRPC","enrollment":90},{"nctId":"NCT06633419","phase":"PHASE1","title":"A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-12-18","conditions":"Healthy","enrollment":14},{"nctId":"NCT04404400","phase":"PHASE3","title":"Hydrocortisone and Fludrocortisone for Critical Illness-related Corticosteroid Insufficiency","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-02-17","conditions":"Critical Illness Related Corticosteroids Insufficiency","enrollment":1092},{"nctId":"NCT06566989","phase":"PHASE1","title":"A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-09-19","conditions":"Metastatic Prostate Cancer","enrollment":8},{"nctId":"NCT06554639","phase":"PHASE1","title":"A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-11","conditions":"Prostatic Neoplasms","enrollment":12},{"nctId":"NCT03773822","phase":"PHASE3","title":"Low Dose of Hydrocortisone and Fludrocortisone in Adult Cardiogenic Shock.","status":"COMPLETED","sponsor":"CMC Ambroise Paré","startDate":"2019-04-19","conditions":"Cardiogenic Shock","enrollment":380},{"nctId":"NCT04128137","phase":"PHASE4","title":"Efficacy and Tolerance of Flucortac in Patients With Orthostatic Neurogenic Hypotension","status":"UNKNOWN","sponsor":"H.A.C. PHARMA","startDate":"2020-07-09","conditions":"Neurogenic Orthostatic Hypotension","enrollment":90},{"nctId":"NCT05453214","phase":"PHASE3","title":"Mineralocorticoid Use in COVID-19 Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2021-12-04","conditions":"COVID-19, ARDS","enrollment":10},{"nctId":"NCT01473108","phase":"PHASE1","title":"Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-03-29","conditions":"Clinical Pharmacology","enrollment":67},{"nctId":"NCT01030874","phase":"NA","title":"Orthostatic Hypotension Treatment on Rehab Unit","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2011-10","conditions":"Orthostatic Hypotension, Falls","enrollment":356},{"nctId":"NCT04595942","phase":"PHASE3","title":"Midodrine and Fludrocortisone for Vasovagal Syncope","status":"UNKNOWN","sponsor":"Tehran Heart Center","startDate":"2020-11-19","conditions":"Syncope, Vasovagal","enrollment":1375},{"nctId":"NCT03001089","phase":"PHASE2","title":"Impact of the Administration of Fludrocortisone in Very Premature Infants","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-01","conditions":"Partial Mineralocorticoid Deficiency","enrollment":66},{"nctId":"NCT00625209","phase":"PHASE3","title":"Activated Protein C and Corticosteroids for Human Septic Shock","status":"COMPLETED","sponsor":"University of Versailles","startDate":"2008-03","conditions":"Septic Shock","enrollment":1241},{"nctId":"NCT02532998","phase":"PHASE1","title":"A Study to Assess the Pharmacodynamic Effect of Single Doses of AZD9977 in Healthy Male Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-09","conditions":"Pharmacodynamics, Healthy Subjects","enrollment":40},{"nctId":"NCT00117585","phase":"NA","title":"Orthostatic Hypotension in Rehabilitation Patients","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2005-11","conditions":"Hypotension, Orthostatic","enrollment":341},{"nctId":"NCT02069288","phase":"PHASE3","title":"Effects of Fludrocortisone on Norepinephrine-mean Arterial Pressure Dose-response in Septic Shock","status":"WITHDRAWN","sponsor":"Rennes University Hospital","startDate":"","conditions":"Septic Shock","enrollment":""},{"nctId":"NCT00673270","phase":"PHASE1, PHASE2","title":"Effects of Fludrocortisone and Hydrocortisone in Healthy Volunteers With Aldosterone Induced Suppression","status":"TERMINATED","sponsor":"Rennes University Hospital","startDate":"2008-05","conditions":"Renin Angiotensin","enrollment":13}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Florinef"],"phase":"phase_3","status":"active","brandName":"Fludrocortisone Acetate Tablets","genericName":"Fludrocortisone Acetate Tablets","companyName":"Tehran Heart Center","companyId":"tehran-heart-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fludrocortisone acetate is a synthetic mineralocorticoid that enhances sodium reabsorption and potassium excretion in the distal renal tubules, thereby increasing blood volume and blood pressure. Used for Acute hypotension / shock, Adrenocortical insufficiency, Salt-wasting syndromes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}